-
Something wrong with this record ?
New uses of halofuginone to treat cancer
R. Zuo, X. Guo, X. Song, X. Gao, J. Zhang, S. Jiang, V. Adam, K. Kuca, W. Wu, D. Guo
Status not-indexed Language English Country China
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2017-02-01
Open Access Digital Library
from 2011-02-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
- Publication type
- Journal Article MeSH
- Review MeSH
The small-molecule alkaloid halofuginone (HF) is obtained from febrifugine. Recent studies on HF have aroused widespread attention owing to its universal range of noteworthy biological activities and therapeutic functions, which range from parasite infections and fibrosis to autoimmune diseases. In particular, HF is believed to play an excellent anticancer role by suppressing the proliferation, adhesion, metastasis, and invasion of cancers. This review supports the goal of demonstrating various anticancer effects and molecular mechanisms of HF. In the studies covered in this review, the anticancer molecular mechanisms of HF mainly included transforming growth factor-β (TGF-β)/Smad-3/nuclear factor erythroid 2-related factor 2 (Nrf2), serine/threonine kinase proteins (Akt)/mechanistic target of rapamycin complex 1(mTORC1)/wingless/integrated (Wnt)/β-catenin, the exosomal microRNA-31 (miR-31)/histone deacetylase 2 (HDAC2) signaling pathway, and the interaction of the extracellular matrix (ECM) and immune cells. Notably, HF, as a novel type of adenosine triphosphate (ATP)-dependent inhibitor that is often combined with prolyl transfer RNA synthetase (ProRS) and amino acid starvation therapy (AAS) to suppress the formation of ribosome, further exerts a significant effect on the tumor microenvironment (TME). Additionally, the combination of HF with other drugs or therapies obtained universal attention. Our results showed that HF has significant potential for clinical cancer treatment.
Central European Institute of Technology Brno University of Technology Brno 60200 Czech Republic
Department of Chemistry and Biochemistry Mendel University in Brno Brno 61300 Czech Republic
School of Food and Biological Engineering Hefei University of Technology Hefei 230009 China
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25008297
- 003
- CZ-PrNML
- 005
- 20250422095746.0
- 007
- ta
- 008
- 250408s2025 cc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpha.2024.101080 $2 doi
- 035 __
- $a (PubMed)40099206
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a cc
- 100 1_
- $a Zuo, Runan $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China $u Animal-Derived Food Safety Innovation Team, Anhui Province Key Lab of Veterinary Pathobiology and Disease Control, College of Animal Science and Technology, Anhui Agricultural University, Hefei, 230036, China
- 245 10
- $a New uses of halofuginone to treat cancer / $c R. Zuo, X. Guo, X. Song, X. Gao, J. Zhang, S. Jiang, V. Adam, K. Kuca, W. Wu, D. Guo
- 520 9_
- $a The small-molecule alkaloid halofuginone (HF) is obtained from febrifugine. Recent studies on HF have aroused widespread attention owing to its universal range of noteworthy biological activities and therapeutic functions, which range from parasite infections and fibrosis to autoimmune diseases. In particular, HF is believed to play an excellent anticancer role by suppressing the proliferation, adhesion, metastasis, and invasion of cancers. This review supports the goal of demonstrating various anticancer effects and molecular mechanisms of HF. In the studies covered in this review, the anticancer molecular mechanisms of HF mainly included transforming growth factor-β (TGF-β)/Smad-3/nuclear factor erythroid 2-related factor 2 (Nrf2), serine/threonine kinase proteins (Akt)/mechanistic target of rapamycin complex 1(mTORC1)/wingless/integrated (Wnt)/β-catenin, the exosomal microRNA-31 (miR-31)/histone deacetylase 2 (HDAC2) signaling pathway, and the interaction of the extracellular matrix (ECM) and immune cells. Notably, HF, as a novel type of adenosine triphosphate (ATP)-dependent inhibitor that is often combined with prolyl transfer RNA synthetase (ProRS) and amino acid starvation therapy (AAS) to suppress the formation of ribosome, further exerts a significant effect on the tumor microenvironment (TME). Additionally, the combination of HF with other drugs or therapies obtained universal attention. Our results showed that HF has significant potential for clinical cancer treatment.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Guo, Xinyi $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China $u School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China
- 700 1_
- $a Song, Xinhao $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China
- 700 1_
- $a Gao, Xiuge $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China
- 700 1_
- $a Zhang, Junren $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China
- 700 1_
- $a Jiang, Shanxiang $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China
- 700 1_
- $a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, 61300, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Brno, 60200, Czech Republic
- 700 1_
- $a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, 50003, Czech Republic $u Malaysia-Japan International Institute of Technology (MJIIT), University Teknologi Malaysia, Kuala Lumpur, 50200, Malaysia
- 700 1_
- $a Wu, Wenda $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China $u School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China
- 700 1_
- $a Guo, Dawei $u Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Ministry of Education Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China
- 773 0_
- $w MED00205566 $t Journal of pharmaceutical analysis $x 2214-0883 $g Roč. 15, č. 3 (2025), s. 101080
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40099206 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250408 $b ABA008
- 991 __
- $a 20250422095747 $b ABA008
- 999 __
- $a ok $b bmc $g 2306328 $s 1245372
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 15 $c 3 $d 101080 $e 20240824 $i 2214-0883 $m Journal of pharmaceutical analysis $n J Pharm Anal $x MED00205566
- LZP __
- $a Pubmed-20250408